08143 GF HEALTHCARE
- 0.137
- +0.011+8.73%
GF HEALTHCARE News
Jinwei Medical (08143): Beijing Bauhinia operations have fully resumed
According to the Zhitong Finance App, Jinwei Medical (08143) issued an announcement. The on-site inspection and inspection of Beijing Bauhinia has been properly completed, and the Health Commission has re-issued a medical institution practice license to Beijing Bauhinia on April 16, 2024. After the medical institution's license was re-issued, the operation of Beijing Bauhinia fully resumed on the date of this announcement.
Jinwei Healthcare (08143): Lin Yaomin was appointed as an independent non-executive director
According to Zhitong Finance App, Jinwei Healthcare (08143) announced that Lin Yaomin has been appointed as an independent non-executive director and a member of the Company Audit Committee, Remuneration Committee, and Nomination and Corporate Governance Committee with effect from April 17, 2024.
Jinwei Medical (08143) Affiliated to Proposes to Lease Hong Kong Properties for Use as Office Space
According to Zhitong Finance App, Jinwei Healthcare (08143) announced that on March 20, 2024, the tenant (Jinwei Innovation Co., Ltd., an indirect wholly-owned subsidiary of the company) and the owner (Huamin Property Co., Ltd.) signed a lease agreement to lease the property. The rental period is 2 years, from February 1, 2024 to January 31, 2026 (including the first and last two days). The total rent is HK$108,800 per month. According to reports, the property is located in Room 3309, 33rd Floor, Shun Tak Centre West Wing, 168-200 Connaught Road Central, Hong Kong, China. The company intends to use the property as a group office property.
GF HEALTHCARE: Interim Report 2023/2024
GF HEALTHCARE: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023
Jinwei Healthcare (08143): The stock merger will take effect on September 13
According to Zhitong Financial App, Jinwei Healthcare (08143) announced that the GEM Listing Committee of the Stock Exchange has granted approval for the listing and trading of the consolidated shares that have been and will be issued after the share merger takes effect and the consolidated shares to be issued when exercising conversion rights attached to the consolidated preferred shares to be issued. Since all the prerequisites for the share consolidation have been met, the share merger will take effect on September 13, 2023 (Wednesday). Trading of the consolidated shares will commence on September 13, 2023 (Wednesday) at 9:00 a.m. (Hong Kong time) on the Stock Exchange.
Jinwei Healthcare (08143): Wu Qiyou appointed as Executive Director and Member of the Remuneration Committee
Jinwei Healthcare (08143) announced that the following changes will take effect from August 22, 2023:1. Zheng Gang has resigned...
GF HEALTHCARE: First Quarterly Report 2023/2024
GF HEALTHCARE: FIRST QUARTERLY RESULTS ANNOUNCEMENT FOR THE THREE MONTHS ENDED 30 JUNE 2023
GF HEALTHCARE: Annual Report 2022/2023
Jinwei Healthcare (08143.HK)'s annual revenue was approximately HK$55.353 million, up about 2.06% year-on-year
Gelonghui, June 16, 丨 Jinwei Healthcare (08143.HK) announced that the Group's financial results for the fiscal year ending March 31, 2023, revenue was approximately HK$55,353 million, an increase of about 2.06% over last year. Operating losses from operating the business were approximately HK$5,237 million (2022: approximately HK$5.891 million). The net loss attributable to the owners of the company was approximately HK$5,881 million. The directors are not recommending payment of a final dividend for the year ending March 31, 2023 (2022: none). For the year ended March 31, 2023, the Group operated a complex in Beijing, China
GF HEALTHCARE: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 MARCH 2023
GF HEALTHCARE: NOTICE OF BOARD MEETING
Jinwei Healthcare: Third Quarter Results Report 2022/2023
Jinwei Healthcare (08143.HK) turned profit and loss to HK$1.077 million in the first 9 months
Gelonghui, Feb. 8 丨 Jinwei Healthcare (08143.HK) announced that for the nine months ending December 31, 2022, the Group has recorded a total turnover of about HK$409.84 million, an increase of about 2.54% over the previous year. The loss attributable to the company owner was approximately HK$1,077 million (2021: profit attributable to the owner of the company is approximately HK$2,729 million). The shift from profit to loss was mainly due to the fact that there was no one-time income of about HK$31.7 million from the sale of subsidiaries during the same period. The directors are not recommending dividends for the nine months ending December 31, 2022 (2021: none). Group business
Jinwei Healthcare: THIRD QUARTERLY RESULTS ANNOUNCEMENT FOR THE NINE MONTHS ENDED DECEMBER 31, 2022
Jinwei Healthcare (08143.HK) Earning Police: Expected loss of HK$10.5 million in the first September
Gelonghui, Feb. 2 丨 Jinwei Healthcare (08143.HK) announced that for the nine months ending December 31, 2022, the Group expects to record a loss of approximately HK$10.5 million during this period, while profit of about HK$6.9 million for the corresponding period in 2021. The projected profit and loss is mainly due to one-time proceeds from the sale of subsidiaries of approximately HK$31.7 million during the corresponding period.
Kingway Medical: interim report 2022 Universe 2023
Kingway Medical (08143) released its interim results, with a loss of HK $6.71 million attributable to shareholders compared with the same period last year.
Zhitong Financial APP News, Kingway Medical (08143) released results for the six months ended September 30, 2022, the group achieved a profit of HK $28.4 million, an increase of 7.72% over the same period last year; the company's owners should share a loss of HK $6.71 million, compared with a profit of HK $7.206 million in the same period last year; a basic loss of HK $0.238 per share. The announcement said that the change from profit to loss was mainly due to an one-time gain of about HK $31.7 million from the sale of subsidiaries in the same period.
Kingway Medical: announcement of interim results for the six months ended September 30, 2022
Analysis
Price Target
No Data
